Clinical Trials
36 trialsMAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Zelluna Immunotherapy AS
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
IGNYTE-ESO
USWM, LLC (dba US WorldMeds)
CLOVER-2
Cellectar Biosciences, Inc.
APROMISS
Advenchen Laboratories, LLC
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Takara Bio Inc.
SPEARHEAD-3 Pediatric Study
USWM, LLC (dba US WorldMeds)
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
USWM, LLC (dba US WorldMeds)
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
ACTengine® IMA203 Combined With mRNA-4203
Immatics US, Inc.
TRuST
Ipsen
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Ipsen
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Foghorn Therapeutics Inc.
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
EPITOME-1015-I
Medigene AG
ROOT
Taproot Health
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
C4 Therapeutics, Inc.
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
Takara Bio Inc.
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Ipsen
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
OncoTherapy Science, Inc.
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Genentech, Inc.
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Eli Lilly and Company
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
GlaxoSmithKline
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Oncolytics Biotech
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Daiichi Sankyo